leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Antithrombotic Drugs Market 2017-2027

Antithrombotic Drugs Market 2017-2027

Anticoagulants, Antiplatelets, Fibrinolytics

Product code: PHA0211

  • Publication date: 12/07/2017
  • Number of Pages: 185
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelets, Fibrinolytics
The revenue of the antithrombotic drugs market in 2016 is estimated at $18.08bn and is expected to grow at a CAGR of 7.9% in the first half of the forecast period. The anticoagulants segment accounted for the largest share of the market in 2016, this segment held 58.5% of the antithrombotic drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 185-page report you will receive 84 tables and 69 figures – all unavailable elsewhere.

The 185-page report provides clear detailed insight into the antithrombotic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Antithrombotic drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main submarkets:
• Anticoagulants
• Antiplatelet agents
• Fibrinolytic treatments

This report provides the revenue forecast for these anticoagulant agents:
• Direct factor Xa inhibitors
• Heparins
• Direct thrombin inhibitors
• Vitamin K antagonists

• This report provides the revenue forecast for the leading products in this market:
• Xarelto
• Plavix
• Lovenox
• Eliquis
• Pradaxa
• Activase
• Brilinta/Brilique
• Aspirin Cardio
• Effient
• Aggrenox/Asasantin
• Fragmin
• Pletal
• Angiomax/Angiox
• Rest of Market

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• US
• Germany
• France
• UK
• Italy
• Spain
• Japan
• China
• Brazil
• Russia
• India
• Rest of World

Antithrombotic Drugs Market 2017-2027

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT and STEP analysis of the antithrombotic drugs market.

• Our study discusses the selected leading companies that are the major players in the antithrombotic drugs market:
• Bayer
• Bristol Myers Squibb
• Sanofi
• Boehringer-Ingelheim
• Roche (Genentech)
• AstraZeneca
• Eli Lilly
• Pfizer
• Otsuka Pharmaceutical
• The Medicines Company

Visiongain’s study is intended for anyone requiring commercial analyses for the antithrombotic drugs market. You find data, trends and predictions.

Buy our report today Antithrombotic Drugs Market 2017-2027: Anticoagulants, Antiplatelets, Fibrinolytics.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1 Overview of the World Market for Antithrombotic Drugs
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Glossary of Abbreviations

2. Blood Clotting: Mechanisms, Disorders and Current Treatments
2.1 Understanding Haemostasis and Coagulation
2.2 What is Thrombosis
2.3 Complications of Thrombosis
2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
2.4 Antithrombotic Drug Treatment

3. Antithrombotic Drugs: World Market 2017-2027
3.1 The World Antithrombotic Drug Market in 2015 and 2016
3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2016-2027
3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
3.3.1 An Increasing Patient Population Drives Market Growth
3.3.2 Intense Competition from Generics Threatens to Restrain the Market
3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2016-2027
3.6 Anticoagulant Drugs: Leading the Market from 2016 Onwards
3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class with Great Potential
3.6.2 Heparins: The Second-Leading Anticoagulant Class in 2016
3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2015 and 2016
3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2016
3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4. Leading Products in the Market: Prospects, 2017-2027
4.1 Xarelto and Eliquis Remain the Market Leaders in 2016, Despite Generic Competition
4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2022 and 2027
4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2027?
4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
4.4.1 Branded Competition for Plavix?
4.5 Lovenox: Biosimilar Competition in the EU is Expected
4.6 Xarelto: Leading Antithrombotic of 2015
4.7 Pradaxa’s Continued Growth in 2016
4.8 Activase Leads the Fibrinolytics Market, With Little Competition
4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
4.14 Fragmin Faces Rivalry from Generic Competition to Lovenox
4.15 Brilinta/Brilique: Investigation Closed in 2014
4.16 Eliquis: Will Late Entry to the Market Affect Uptake?
4.17 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
4.18 New Approvals in the Antithrombotic Drugs Market
4.18.1 Zontivity: The Newest Approval In Antithrombotics
4.18.2 Lixiana/Savaysa: Expansion into Other Regional Markets

5. Leading National Markets 2016-2027
5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2015 and 2016?
5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2021 and 2027
5.3 Which National Markets Will Grow Fastest to 2027?
5.4 The US: Dominating the Antithrombotic Drug Market Through 2016-2027
5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
5.5.1 Germany Leads the EU5
5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
5.5.3 UK: Pharmaceutical Price Regulation Scheme
5.5.4 Italy’s Healthcare System - Advantages Conducive to Business
5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2017-2027
5.7 The Chinese Antithrombotic Drug Market Will Capture Market Share
5.8 The Brazilian Antithrombotic Drug Market 2017-2027: Strong Growth as Universal Healthcare Coverage is Expanded
5.9 The Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?
5.10 The Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth

6. Antithrombotic Drug Development: R&D Pipeline
6.1 The R&D Pipeline for Antithrombotic Drugs: Overview
6.2 The Antiplatelet Drug R&D Pipeline in 2016
6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
6.2.2 The Medicines Company’s Kangrexel (Cangrelor) Received Approval
6.3 The R&D Pipeline for Anticoagulants, 2016
6.3.1 Heparins: Little R&D Activity in 2016
6.3.2 The Vitamin K Antagonist Pipeline
6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
6.3.5 Portola Pharmaceuticals’ Betrixaban
6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
6.4 The Fibrinolytics R&D Pipeline, 2016
6.4.1 Lundbeck’s Desmoteplase: Failed to Meet Primary Endpoint in Phase III
6.4.2 Bharat Biotech and ThromboGenics’ THR-100
6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2016
6.5.1 Kyowa Hakko Kirin’s KW-3357: Filed in Japan
6.5.2 Asahi Kasei Pharma America’s ART 123
6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
6.5.4 Isis Pharmaceuticals’ ISIS-FXI Rx

7. Leading Companies in the Antithrombotic Drug Market
7.1 Leading Antithrombotic Drug Manufacturers in 2015 and 2016
7.2 Sanofi Leads the Market, but is its Position Under Threat?
7.3 Boehringer Ingelheim Captures Market Share
7.4 Bayer Markets Two Antithrombotic Drugs
7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio
7.6 Genentech Will Retain Market Share
7.7 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug
7.8 Eli Lilly: Market Position is Dependent on Success of Effient
7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
7.10 Pfizer: A Gradually Increasing Share of the Market
7.11 Bristol-Myers Squibb Expected to Lead the Market 2017 onwards

8. Qualitative Analysis of the Antithrombotic Drugs Market, 2016
8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2016
8.1.1 Thrombotic Disease: Management Rather Than Cure
8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
8.2 Opportunities and Threats Facing the Market 2016-2027
8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
8.2.2 Further Development of Existing Drugs
8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
8.2.4 The Threat of Generic Competition
8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
8.2.6 High Risk of Investment in New Drug Development
8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2017-2027
8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
8.3.3 Economic Factors
8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?

9. Conclusions from Our Study
9.1 The World Market for Antithrombotic Drugs 2017-2027
9.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
9.2 The Leading National Markets 2017-2027
9.3 Trends in the Industry
9.3.1 The Market Will Recover From Plavix Decline
9.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
9.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
9.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications

Appendices
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016
Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2015 and 2016
Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.3 The Antithrombotic Drug Market by Therapeutic
Class: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027
Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027
Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027
Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.9 The Warfarin Market: Companies and Year of Introduction
Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016
Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
Table 4.4 Plavix: Key Facts, 2016
Table 4.5 Selected Generic Competitors Approved by the FDA, 2016
Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.7 Lovenox: Key Facts, 2016
Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.9 Xarelto: Key Facts, 2016
Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.11 Pradaxa: Key Facts, 2014
Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.13 Activase: Key Facts, 2016
Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.15 Effient: Key Facts, 2016
Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.17 Aspirin Cardio: Key Facts, 2016
Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.19 Angiomax/Angiox: Key Facts, 2016
Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.21 Pletal: Key Facts, 2016
Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.23 Aggrenox/Asasantin: Key Facts, 2016
Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.25 Fragmin: Key Facts, 2016
Table 4.26 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.27 Brilinta: Key Facts, 2016
Table 4.28 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.29 Eliquis: Key Facts, 2016
Table 4.30 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 4.31 Arixtra: Key Facts, 2016
Table 4.32 Zontivity: Key Facts, 2016
Table 4.33 Lixiana/Savaysa: Key Facts, 2016
Table 5.1 The Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2015 and 2016
Table 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2021 and 2027
Table 5.3 The Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2016-2027
Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2016
Table 6.2 Selected Candidates in the Heparins Pipeline, 2016
Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014
Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2016
Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2016
Table 6.6 The Fibrinolytics R&D Pipeline, 2016
Table 6.7 Other Antithrombotic Drugs in Development, 2016
Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2015 and 2016
Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2016
Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2016
Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2016
Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2016
Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2016
Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2016
Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2016
Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2016
Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2016
Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2016
Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2016
Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2016-2027
Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2017-2027

List of Figures
Figure 2.1 Diagram Depicting the Coagulation Cascade
Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2015
Figure 3.2 The Antithrombotic Drug Market by Therapeutic
Class: Market Share (%), 2016
Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m), 2016-2027
Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2021
Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2027
Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2016-2027
Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2016-2027
Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2016-2027
Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2017-2027
Figure 3.11 Heparins: Revenue Forecast ($m), 2016-2027
Figure 3.12 The Heparins Market: Drivers and Restraints, 2017-2027
Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2016-2027
Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2017-2027
Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2016-2027
Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2016-2027
Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2016-2027
Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2017-2027
Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2016-2027
Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2017-2027
Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2015
Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2016
Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2022
Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2027
Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
Figure 4.6 Plavix: Revenue Forecast ($m), 2016-2027
Figure 4.7 Lovenox: Revenue Forecast ($m), 2016-2027
Figure 4.8 Xarelto: Revenue Forecast ($m), 2016-2027
Figure 4.9 Pradaxa: Revenue Forecast ($m), 2016-2027
Figure 4.10 Activase: Revenue Forecast ($m), 2016-2027
Figure 4.11 Effient: Revenue Forecast ($m), 2016-2027
Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2016-2027
Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2016-2027
Figure 4.14 Pletal: Revenue Forecast ($m), 2016-2027
Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2016-2027
Figure 4.16 Fragmin: Revenue Forecast ($m), 2016-2027
Figure 4.17 Brilinta: Revenue Forecast ($m), 2016-2027
Figure 4.18 Eliquis: Revenue Forecast ($m), 2014-2025
Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2015
Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2016
Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2021
Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2027
Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2016-2027
Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2016-2027
Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2016-2027
Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2016-2027
Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2017-2027
Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2016
Figure 7.1 The Top 10 Companies: Market Shares (%), 2015
Figure 7.2 The Top 10 Companies: Market Shares (%), 2016
Figure 9.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2015-2027
Figure 9.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2016, 2021 and 2027

Companies Listed

Abbott Laboratories
Ablynx
Aché
Accord Healthcare
Actavis Totowa
AdvanceCor GmbH
Alchemia
Amneal Pharms
Amphastar Pharmaceuticals
Apotex
App Pharmaceuticals
ARCA biopharma
Armetheon
ARYx Therapeutics
Asahi Kasei Pharma America
Aspen
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Laboratories (subsidiary of Barr Pharmaceuticals)
Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
Bayer
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Capital TEN II
Canyon Pharmaceuticals
CSL Behring
Daiichi Sankyo
Dexa Medica
Diakron Pharmaceuticals
Dr. Reddy’s Laboratories
DuPont Merck
Eisai
Eli Lilly
EMS
Endo Laboratories
ESP Pharma
Eurofarma
Fournier Pharma
Gate Pharmaceuticals
Genentech
GlaxoSmithKline (GSK)
Grifols Therapeutics
Hercules Bioventures Partners
Hoechst Marion Roussell
Hospira
Hypermarcas
Invagen Pharms
IPCA Labs
Isis Pharmaceuticals
Johns Hopkins Medicine
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko Kirin
Lee’s Pharmaceutical
LG Life Sciences
LIMES Institute
Lundbeck
Macleods Pharmaceuticals
Merck & Co.
Mitsubishi
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mutual Pharmaceuticals
Mylan Pharmaceuticals
Novartis
Nuvelo
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmacia
PLIVA
PLx Pharma
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Roxane Laboratories
Sandoz
Sanofi
ScieGen Pharmaceuticals
Sun Pharmaceuticals Indusdtries
Takeda
Taro
Teva Pharmaceutical Industries
The Medicines Company
ThromboGenics
Tianjin Medical
Tobira Therapeutics
Torrent Pharmaceuticals
Tufts Medical Center
Upjohn AB
USL Pharma
Wockhardt
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
Zydus Cadila
Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)

Organizations Mentioned in the Report
Baylor College of Medicine, Houston, Texas
Committee on Medicinal Products for Human Use (CHMP)
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
German Institute for Quality and Efficiency in Health Care (IQWiG)
Indonesia University
Judicial Panel on Multidistrict Litigation (US)
National Health Service (NHS)
National Institute for Health and Care Excellence (NICE)
Pharmaceutical and Medical Devices Agency (PMDA)
Unified Health System (SUS)
Universidade Federal de São Paulo
University General Hospital
University of Insubria (Italy)
US Department of Justice
Virginia Commonwealth University
World Health Organization (WHO)

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close